BR112022011372A2 - Inibidores de interação de proteína a de replicação (rpa)-dna - Google Patents

Inibidores de interação de proteína a de replicação (rpa)-dna

Info

Publication number
BR112022011372A2
BR112022011372A2 BR112022011372A BR112022011372A BR112022011372A2 BR 112022011372 A2 BR112022011372 A2 BR 112022011372A2 BR 112022011372 A BR112022011372 A BR 112022011372A BR 112022011372 A BR112022011372 A BR 112022011372A BR 112022011372 A2 BR112022011372 A2 BR 112022011372A2
Authority
BR
Brazil
Prior art keywords
rpa
replication protein
dna interaction
interaction inhibitors
compounds
Prior art date
Application number
BR112022011372A
Other languages
English (en)
Inventor
J Turchi John
Gavande Navnath
Original Assignee
Univ Indiana Trustees
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Trustees filed Critical Univ Indiana Trustees
Publication of BR112022011372A2 publication Critical patent/BR112022011372A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INIBIDORES DE INTERAÇÃO DE PROTEÍNA A DE REPLICAÇÃO (RPA)-DNA. A presente invenção refere-se a compostos de RPA ou sais farmaceutica-mente aceitáveis dos mesmos, e ao uso dos compostos para tratar câncer.
BR112022011372A 2019-12-10 2020-12-10 Inibidores de interação de proteína a de replicação (rpa)-dna BR112022011372A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962946100P 2019-12-10 2019-12-10
PCT/US2020/064191 WO2021119242A1 (en) 2019-12-10 2020-12-10 Replication protein a (rpa)-dna interaction inhibitors

Publications (1)

Publication Number Publication Date
BR112022011372A2 true BR112022011372A2 (pt) 2022-08-23

Family

ID=76330773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011372A BR112022011372A2 (pt) 2019-12-10 2020-12-10 Inibidores de interação de proteína a de replicação (rpa)-dna

Country Status (6)

Country Link
US (1) US20230056729A1 (pt)
EP (1) EP4073055A4 (pt)
JP (1) JP2023505690A (pt)
BR (1) BR112022011372A2 (pt)
CA (1) CA3162280A1 (pt)
WO (1) WO2021119242A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812071A2 (en) * 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
UA100979C2 (ru) * 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
WO2016077752A2 (en) * 2014-11-13 2016-05-19 Indiana University Research And Technology Corporation Materials and method for inhibiting replication protein a and uses thereof

Also Published As

Publication number Publication date
US20230056729A1 (en) 2023-02-23
JP2023505690A (ja) 2023-02-10
CA3162280A1 (en) 2021-06-17
EP4073055A4 (en) 2024-02-28
EP4073055A1 (en) 2022-10-19
WO2021119242A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
BR112022008535A2 (pt) Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
BR112022008534A2 (pt) Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
BR102018002152A8 (pt) Compostos, composições farmacêuticas e seus usos como inibidores de hiv
BR112021023359A2 (pt) Inibidores de g12c de kras e usos dos mesmos
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
BR112018070549A2 (pt) degradantes de proteína mdm2
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112018068956A2 (pt) derivados do composto indol substituídos como inibidores da replicação viral da dengue
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
BR112018068640A2 (pt) derivados de indolina substituídos como inibidores da replicação viral do dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018075135A2 (pt) combinações farmacêuticas para tratar câncer
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
BR112022008365A2 (pt) Inibidores de cd73
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112019000929A2 (pt) derivados de tiofeno condensados úteis como inibidores de napi-iib